ADMA
Price
$19.54
Change
+$0.05 (+0.26%)
Updated
Dec 24 closing price
Capitalization
4.65B
84 days until earnings call
Intraday BUY SELL Signals
CPRX
Price
$24.45
Change
+$0.22 (+0.91%)
Updated
Dec 24 closing price
Capitalization
3.01B
83 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ADMA vs CPRX

Header iconADMA vs CPRX Comparison
Open Charts ADMA vs CPRXBanner chart's image
ADMA Biologics
Price$19.54
Change+$0.05 (+0.26%)
Volume$810.95K
Capitalization4.65B
Catalyst Pharmaceuticals
Price$24.45
Change+$0.22 (+0.91%)
Volume$513.48K
Capitalization3.01B
ADMA vs CPRX Comparison Chart in %
View a ticker or compare two or three
VS
ADMA vs. CPRX commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADMA is a StrongBuy and CPRX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (ADMA: $19.54 vs. CPRX: $24.45)
Brand notoriety: ADMA and CPRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADMA: 25% vs. CPRX: 39%
Market capitalization -- ADMA: $4.65B vs. CPRX: $3.01B
ADMA [@Biotechnology] is valued at $4.65B. CPRX’s [@Biotechnology] market capitalization is $3.01B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADMA’s FA Score shows that 2 FA rating(s) are green whileCPRX’s FA Score has 1 green FA rating(s).

  • ADMA’s FA Score: 2 green, 3 red.
  • CPRX’s FA Score: 1 green, 4 red.
According to our system of comparison, CPRX is a better buy in the long-term than ADMA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADMA’s TA Score shows that 3 TA indicator(s) are bullish while CPRX’s TA Score has 4 bullish TA indicator(s).

  • ADMA’s TA Score: 3 bullish, 5 bearish.
  • CPRX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CPRX is a better buy in the short-term than ADMA.

Price Growth

ADMA (@Biotechnology) experienced а +3.77% price change this week, while CPRX (@Biotechnology) price change was +1.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.88%. For the same industry, the average monthly price growth was +4.46%, and the average quarterly price growth was +55.39%.

Reported Earning Dates

ADMA is expected to report earnings on Mar 19, 2026.

CPRX is expected to report earnings on Mar 18, 2026.

Industries' Descriptions

@Biotechnology (+2.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ADMA($4.65B) has a higher market cap than CPRX($3.01B). ADMA has higher P/E ratio than CPRX: ADMA (22.72) vs CPRX (14.30). CPRX YTD gains are higher at: 17.154 vs. ADMA (13.936). CPRX has higher annual earnings (EBITDA): 297M vs. ADMA (172M). CPRX has more cash in the bank: 690M vs. ADMA (61.4M). CPRX has less debt than ADMA: CPRX (2.89M) vs ADMA (83.1M). CPRX has higher revenues than ADMA: CPRX (578M) vs ADMA (489M).
ADMACPRXADMA / CPRX
Capitalization4.65B3.01B155%
EBITDA172M297M58%
Gain YTD13.93617.15481%
P/E Ratio22.7214.30159%
Revenue489M578M85%
Total Cash61.4M690M9%
Total Debt83.1M2.89M2,876%
FUNDAMENTALS RATINGS
ADMA vs CPRX: Fundamental Ratings
ADMA
CPRX
OUTLOOK RATING
1..100
7320
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
63
Fair valued
PROFIT vs RISK RATING
1..100
2820
SMR RATING
1..100
1735
PRICE GROWTH RATING
1..100
4546
P/E GROWTH RATING
1..100
9878
SEASONALITY SCORE
1..100
n/a6

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CPRX's Valuation (63) in the Pharmaceuticals Other industry is in the same range as ADMA (75) in the Biotechnology industry. This means that CPRX’s stock grew similarly to ADMA’s over the last 12 months.

CPRX's Profit vs Risk Rating (20) in the Pharmaceuticals Other industry is in the same range as ADMA (28) in the Biotechnology industry. This means that CPRX’s stock grew similarly to ADMA’s over the last 12 months.

ADMA's SMR Rating (17) in the Biotechnology industry is in the same range as CPRX (35) in the Pharmaceuticals Other industry. This means that ADMA’s stock grew similarly to CPRX’s over the last 12 months.

ADMA's Price Growth Rating (45) in the Biotechnology industry is in the same range as CPRX (46) in the Pharmaceuticals Other industry. This means that ADMA’s stock grew similarly to CPRX’s over the last 12 months.

CPRX's P/E Growth Rating (78) in the Pharmaceuticals Other industry is in the same range as ADMA (98) in the Biotechnology industry. This means that CPRX’s stock grew similarly to ADMA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADMACPRX
RSI
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
71%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 4 days ago
80%
Declines
ODDS (%)
Bearish Trend 8 days ago
75%
Bearish Trend 8 days ago
67%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
79%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
ADMA
Daily Signal:
Gain/Loss:
CPRX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FRSGX37.950.14
+0.37%
Franklin Small-Mid Cap Growth A
AZBAX24.340.05
+0.21%
Virtus Small-Cap A
RSEGX60.540.05
+0.08%
Victory RS Small Cap Growth A
LMCFX33.820.02
+0.06%
Lord Abbett Mid Cap Stock F
FBAKX32.28N/A
N/A
Fidelity Balanced K

ADMA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADMA has been loosely correlated with VIR. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ADMA jumps, then VIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADMA
1D Price
Change %
ADMA100%
+0.26%
VIR - ADMA
42%
Loosely correlated
+2.00%
IMTX - ADMA
40%
Loosely correlated
+1.47%
CPRX - ADMA
39%
Loosely correlated
+0.91%
XENE - ADMA
39%
Loosely correlated
+1.06%
RGNX - ADMA
38%
Loosely correlated
+0.77%
More

CPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CPRX has been loosely correlated with VIR. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if CPRX jumps, then VIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CPRX
1D Price
Change %
CPRX100%
+0.91%
VIR - CPRX
53%
Loosely correlated
+2.00%
SANA - CPRX
49%
Loosely correlated
N/A
IRON - CPRX
41%
Loosely correlated
+0.76%
LGND - CPRX
40%
Loosely correlated
-0.13%
ARWR - CPRX
40%
Loosely correlated
+0.40%
More